Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 3/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19690341 | 0.93 | NOTUM (0.47) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL14158701 | 0.80 | NOTUM (0.43) | UCHL1HDAC1HDAC6NOTUMMEN1 | |
| SCHEMBL20571008 | 0.80 | UCHL1 (0.61) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL30147617 | 0.80 | UCHL1 (0.61) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL3132755 | 0.80 | NOTUM (0.54) | KDM1AHDAC1HDAC6NOTUMBCHE | |
| SCHEMBL307163 | 0.78 | NOTUM (0.45) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL29753157 | 0.78 | NOTUM (0.45) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL29753484 | 0.77 | HDAC1 (0.47) | KDM1AHDAC1HDAC6NOTUMBCHE | |
| SCHEMBL29535019 | 0.77 | UCHL1 (0.67) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL1284259 | 0.77 | UCHL1 (0.67) | UCHL1KDM1AHDAC1HDAC6NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209652-B1 | TRICYCLIC ATROPISOMER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10023534-B2 | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170355673-A1 | TRICYCLIC ATROPISOMER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355673-A1 | TRICYCLIC ATROPISOMER COMPOUNDS | BTK, LCK, SYK | UCHL1 3170/4885KDM1A 1432/4885HDAC1 499/4885 |
| US-20140155375-A1 | NOVEL COMPOUNDS | CYBB, NOX1, NOX4 | UCHL1 2838/4885KDM1A 3166/4885HDAC1 459/4885 |
| US-10023534-B2 | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK | BTK, JAK2, SYK | UCHL1 3173/4885KDM1A 495/4885HDAC1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.